Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch, Johannes S. De Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L.L. Adams, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha Van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob De Vries, Marjolijn N. Lub-De Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther De Boer, Bert Van Der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina OliveiraArjen J. Witkamp, Willem P.Th M. Mali, Elsken Van Der Wall, P. Beatriz Garcia-Allende, Paul J. Van Diest, Elisabeth G.E. De Vries, Axel Walch, Gooitzen M. Van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original languageEnglish
Title of host publicationClinical and Preclinical Optical Diagnostics
EditorsJ. Quincy Brown, Ton G. van Leeuwen
PublisherSPIE
ISBN (Electronic)9781510612808
DOIs
StatePublished - 2017
EventClinical and Preclinical Optical Diagnostics 2017 - Munich, Germany
Duration: 25 Jun 201727 Jun 2017

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume10411
ISSN (Print)1605-7422

Conference

ConferenceClinical and Preclinical Optical Diagnostics 2017
Country/TerritoryGermany
CityMunich
Period25/06/1727/06/17

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold'. Together they form a unique fingerprint.

Cite this